Navigation Links
Nestle Nutrition and Phosphagenics to Commence Phospha E(R) Phase 2 Clinical Trial
Date:10/4/2007

MELBOURNE, Australia, Oct. 4 /PRNewswire-FirstCall/ -- Phosphagenics Limited (ASX: POH, AIM: PSG, OTCQX: PPGNY) and Nestle Nutrition (Nestle) today announced that they will jointly commence a phase 2 human clinical trial in Australia to establish the efficacy of Phosphagenics' Phospha E(R) in the management of metabolic syndrome.

Ethics approval has been obtained to conduct the double-blind phase 2 clinical trial, which will commence shortly.

Metabolic syndrome is characterized by a group of risk factors that increase the risk of diabetes, coronary heart disease and other diseases associated with plaque build up in artery walls, such as stroke. The American Heart Association estimates that 47 million U.S. residents have metabolic syndrome.

Dr. Esra Ogru, Executive Vice President Research & Development at Phosphagenics, said: "It is very rewarding to see Phospha E progress down the clinical trial path after years of pre-clinical testing. We have reached a very exciting stage of the development of this product and are delighted to be aligned with the world's largest nutrition company as our partner."

Nestle will fund the phase 2 clinical trials and will be granted a worldwide exclusive license for the use of Phospha E in medical foods, while Phosphagenics will manufacture and supply Phospha E to Nestle. The final commercial arrangements are expected to be completed by the end of this year.

This new collaboration builds upon two pre-clinical dose response trials performed by Nestle and Phosphagenics in 2006. The results of these trials confirmed that, when given orally, Phospha E significantly reduced many of the key biomarkers associated with metabolic syndrome, inflammation and cardiovascular disease.

About Phosphagenics Limited

Phosphagenics is a Melbourne-based, globally driven biotechnology company focused on the discovery of new and cost effective ways to enhance the bioavailability, activity, safety and delivery o
'/>"/>

SOURCE Phosphagenics Limited
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
2. Phosphagenics to Commence Phase 1b Transdermal Insulin Clinical Trial in Second Quarter
3. LANI completes Phase I in Japan and to commence Phase I in UK
4. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
5. New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel
6. AM-Pharma Announces Positive Results of a Phase IIa Clinical Trial with Alkaline Phosphatase in Acute Renal Failure
7. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
8. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... -- Lakeland Industries, Inc. (NASDAQ: LAKE ), a ... and to first responders on the federal, state and ... fiscal 2013 fourth quarter and year ended January 31, ... close and will conduct a conference call on the ... http://photos.prnewswire.com/prnh/20120611/NY21959LOGO ) The call will ...
(Date:5/17/2013)... May 17, 2013  Sony Biotechnology Inc. ("Sony") today announced ... holder and 130um sorting chip.  Sony will also be exhibiting ... new SH800 Cell Sorter, the EC800 flow cytometer, and new ... CYTO 2013, which will be held at the ... Diego, California , from May 20 - 22.  ...
(Date:5/17/2013)... , May 17, 2013  ConvaTec today announced that it will ... Ken Berger , CEO, and Ed Borkowski ... ET live via telephone. To participate in the conference ... 366-0267. To participate in the conference call outside the U.S. ... The conference ID is 72195398. Participants should dial in 10 ...
Breaking Medicine Technology:Lakeland Industries to Report Fiscal Fourth Quarter and Year End Financial Results and Conduct Conference Call 2Sony Delivers New Technology for Science to CYTO 2013 2
... (Soligenix or the Company) (OTC Bulletin Board: ... its President and Chief Executive Officer Christopher J. Schaber, ... at the Rodman & Renshaw 12th Annual Healthcare Conference ... on Wednesday, September 15, 2010 at 10:00AM EDT in ...
... Calif., Sept. 10 Sutter Health today announced a donation ... Red Cross to aid in relief efforts following a destructive ... and shelter. The donation is made on behalf of the ... addition to $50,000 generously donated by Sutter-affiliated California Pacific Medical ...
Cached Medicine Technology:Soligenix to Present at the Rodman & Renshaw Healthcare Conference on September 15, 2010 at 10AM EDT 2Soligenix to Present at the Rodman & Renshaw Healthcare Conference on September 15, 2010 at 10AM EDT 3Sutter Health Network Donates $150,000 to Aid Victims of San Bruno Fire 2
(Date:5/18/2013)... 18 (HealthDay News) -- Just a few extra cups ... of an autoimmune liver disease known as primary sclerosing ... the Mayo Clinic in Rochester, Minn., found that drinking ... the disease, which can lead to cirrhosis of the ... does not prove a cause-and-effect relationship. "While ...
(Date:5/18/2013)... are significant cost and risk factors associated with ... gastrointestinal problems, according to research presented at Digestive ... New York Presbyterian Hospital and Weill-Cornell Medical College ... the cost and risk of managing gastroesophageal reflux ... nearly 25 percent of adults, researchers found that ...
(Date:5/18/2013)... May 18, 2013 Assisted living ... comes to safety and comfort of their residents. ... provides clients with an effective and cost-efficient solution ... is an integrated, turnkey communications solution that helps ... allowing residents independence and privacy. , The ...
(Date:5/18/2013)... York (PRWEB) May 18, 2013 ... mesh products continue to move forward in a consolidated ... Bernstein Liebhard LLP reports. According to a notice on ... the Ethicon pelvic mesh litigation will be held on ... complaints have been filed in the proceeding on behalf ...
(Date:5/18/2013)... May 18, 2013 The “World Healthcare ... and studies the major market drivers, restraints, and opportunities ... world. , Browse , 89 ... in-depth TOC on "Healthcare IT Market" , ... customization on reports. , The global healthcare IT market ...
Breaking Medicine News(10 mins):Health News:Study Links Coffee to Lower Risk for Rare Liver Disease 2Health News:New research identifies practice changes to improve value and quality of GI procedures 2Health News:VisionLink Nurse Call System's New Features Serve the Unique Needs of Retirement Communities 2Health News:VisionLink Nurse Call System's New Features Serve the Unique Needs of Retirement Communities 3Health News:Transvaginal Mesh Lawsuits: Bernstein Liebhard LLP Notes Upcoming Case Management Conference in New Jersey Ethicon Pelvic Mesh Litigation 2Health News:Transvaginal Mesh Lawsuits: Bernstein Liebhard LLP Notes Upcoming Case Management Conference in New Jersey Ethicon Pelvic Mesh Litigation 3Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 2Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 3
... the growing shift toward oral chemotherapy agents offers cancer patients ... of the new medications also poses more chances for patients ... in a dangerous way. An increasing number of cancer patients ... click of a pill bottle each day rather than the ...
... 28 Niutang Chemical , one ... in the world, today announced it plans to ... 300 metric tons, within the next three years. ... its sucralose capacity to 1,000 metric tons by 2014.(Logo: ...
... PerformLOS ANGELES, May 28 The Pediatric Inflammatory Bowel ... Producer Alexandra Milchan-Lambert and Relativity Media President of Production ... 2009 at Culver Studios. The afternoon will celebrate ... and will feature a fun-filled day of activities including ...
... WASHINGTON, May 28 The State of Florida took ... children yesterday when Governor Charlie Crist signed a $1 ... legislature through the budget dramatically increased funding for smoking ... toll-free QuitLine (877-U-CAN-NOW).Florida,s cigarette tax had been the fourth ...
... A new statewide poll of registered voters finds ... to give the U.S. Food and Drug Administration (FDA) the ... expected to debate this issue next week, and Senators Webb ... Congress will finally pass this life-saving legislation.(Logo: ...
... many potential new drug targets for cancers long deemed ... contain. These studies are beginning to reveal new ways ... of normal genes that cancer cells rely on for ... Medical Institute (HHMI) investigators D. Gary Gilliland of Brigham ...
Cached Medicine News:Health News:Compliance and cost: Bitter pills to swallow in the age of oral chemotherapy 2Health News:Compliance and cost: Bitter pills to swallow in the age of oral chemotherapy 3Health News:Niutang to Expand Sucralose Capacity 66 Percent by 2012 2Health News:The Pediatric IBD Center at Cedars-Sinai Medical Center Presents Rock-n-Reel 2009 Honoring Alexandra Milchan-Lambert & Scott Lambert 2Health News:Florida's $1 Cigarette Tax Increase a Big Win for Public Health 2Health News:Florida's $1 Cigarette Tax Increase a Big Win for Public Health 3Health News:New Virginia Poll: 71 Percent of Voters Strongly Support FDA Regulation of Tobacco Products 2Health News:New Virginia Poll: 71 Percent of Voters Strongly Support FDA Regulation of Tobacco Products 3Health News:The vulnerable cancer cell 2Health News:The vulnerable cancer cell 3Health News:The vulnerable cancer cell 4Health News:The vulnerable cancer cell 5Health News:The vulnerable cancer cell 6
Toxo IgG ELISA. All Wampole ELISA kits include the following: 12 x 8 well strips with breakaway wells, sample diluent, controls and calibrators, conjugate, TMB substrate, wash buffer, stop solution,...
Herpes Simplex Virus 2 IgG ELISA....
Blunt tipped forceps with tungsten carbide treated jaws for enhanced gripping and removal of large sized foreign bodies....
Blunt tipped forceps with entire interior surface of tip serrated. For general purpose membrane grasping (coarse membranes)....
Medicine Products: